|19.61||+0.2100||+1.08%||Vol 1.26M||1Y Perf -4.76%|
|Jun 24th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||44.50||Analyst Rating||Strong Buy 1.00|
|Potential %||126.93||Finscreener Ranking||★★★ 49.22|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★ 54.88|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★+ 48.62|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||28.37||Earnings Rating||Neutral|
|Market Cap||1.05B||Earnings Date||9th Aug 2022|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||9th Aug 2022|
|Estimated EPS Next Report||-0.62|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||399.53K|
|Avg. Monthly Volume||337.58K|
|Avg. Quarterly Volume||344.88K|
Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) stock closed at 19.61 per share at the end of the most recent trading day (a 1.08% change compared to the prior day closing price) with a volume of 1.26M shares and market capitalization of 1.05B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 68 people. Crinetics Pharmaceuticals Inc. CEO is R. Scott Struthers.
The one-year performance of Crinetics Pharmaceuticals Inc. stock is -4.76%, while year-to-date (YTD) performance is -30.98%. CRNX stock has a five-year performance of %. Its 52-week range is between 15.91 and 28.95, which gives CRNX stock a 52-week price range ratio of 28.37%
Crinetics Pharmaceuticals Inc. currently has a PE ratio of -6.50, a price-to-book (PB) ratio of 3.23, a price-to-sale (PS) ratio of 232.51, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -48.05%, a ROC of -52.14% and a ROE of -52.76%. The company’s profit margin is -%, its EBITDA margin is -2 795.70%, and its revenue ttm is $4.21 Million , which makes it $0.08 revenue per share.
Of the last four earnings reports from Crinetics Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.62 for the next earnings report. Crinetics Pharmaceuticals Inc.’s next earnings report date is 09th Aug 2022.
The consensus rating of Wall Street analysts for Crinetics Pharmaceuticals Inc. is Strong Buy (1), with a target price of $44.5, which is +126.93% compared to the current price. The earnings rating for Crinetics Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Crinetics Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Crinetics Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 8.57, ATR14 : 1.35, CCI20 : 102.88, Chaikin Money Flow : 0.08, MACD : -0.08, Money Flow Index : 70.32, ROC : 0.20, RSI : 55.28, STOCH (14,3) : 65.95, STOCH RSI : 1.00, UO : 54.25, Williams %R : -34.05), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Crinetics Pharmaceuticals Inc. in the last 12-months were: Ajay Madan (Option Excercise at a value of $77 660), Ajay Madan (Sold 13 411 shares of value $239 085 ), Alan Krasner (Option Excercise at a value of $80 467), Alan Krasner (Sold 6 700 shares of value $142 080 ), Matthew K. Fust (Option Excercise at a value of $57 300), Matthew K. Fust (Sold 30 000 shares of value $681 500 ), R. Scott Struthers (Sold 170 000 shares of value $4 510 850 ), Stephen F. Betz (Sold 94 658 shares of value $2 346 606 )
Fri, 10 Jun 2022 12:12 GMT Crinetics Pharmaceuticals (CRNX) Gets a Buy Rating from J.P. Morgan- TipRanks. All rights reserved.
Fri, 27 May 2022 04:37 GMT Crinetics Pharmaceuticals (CRNX) Receives a Buy from Evercore ISI- TipRanks. All rights reserved.
Mon, 16 May 2022 10:17 GMT Crinetics Pharmaceuticals (CRNX) Receives a Buy from H.C. Wainwright- TipRanks. All rights reserved.
Sun, 03 Apr 2022 10:42 GMT Crinetics Pharmaceuticals (CRNX) Receives a Buy from J.P. Morgan- TipRanks. All rights reserved.
Sat, 02 Apr 2022 02:25 GMT Crinetics Pharmaceuticals (CRNX) Receives a Buy from Leerink Partners- TipRanks. All rights reserved.
Thu, 31 Mar 2022 06:55 GMT Crinetics Pharmaceuticals (CRNX) Gets a Buy Rating from JMP Securities- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.